A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
12 August, 2025
TROG 15.03/ANZUP 16001 FASTRACK II: economic analysis shows new technique is cheaper and more effective in the Australian setting
TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer
31 July, 2025
World Lung Cancer Day: Focus on the TROG Lung Working Party
TROG WORKING PARTY IN FOCUS: 31 July 2025 To